Silence Therapeutics plc
NASDAQ:SLNBiotechnology
Healthcare
$19.82 +2.81%
+$0.19 today
- Market cap
- $936.18M
- Beta
- 1.48
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.80
52W Low $4.19High $8.40
Volume 1.47M
Average 0.31M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$62.27M
FY 2025 · Annual
Investing Cash Flow
-$47.99M
FY 2025 · Annual
Financing Cash Flow
$15,000.00
FY 2025 · Annual
-100.0% YoYCash Flow Statement
Mixed currencies
Metric | FY2021 Dec 2021 · GBP | FY2022 Dec 2022 · GBP | FY2023 Dec 2023 · GBP | FY2024 Dec 2024 · GBP | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (61.89M) | (50.33M) | (50.31M) | (28.92M) | (88.61M) |
| Depreciation & Amortization | 576.29K | 596K | 498K | 473.86K | 555K |
| Deferred Income Tax | 5.95M | 688K | 0 | 675.23K | 11K |
| Stock-Based Compensation | 11.65M | 12.69M | 13.05M | 10.41M | 8.07M |
| Change in Working Capital | 52.43M | (19.4M) | (11.66M) | (26.39M) | 10.16M |
| Accounts Receivables | 37.09M | (10.54M) | 314K | (722.38K) | 5.07M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 15.33M | (8.85M) | (11.98M) | (25.67M) | 5.09M |
| Other Non-Cash Items | 468.32K | (1.28M) | 9.07M | (10.3M) | 7.54M |
| Operating Cash Flow | 9.19M | (57.04M) | (39.35M) | (54.05M) | (62.27M) |
| Capital Expenditures | (1.8M) | (545K) | (45K) | (168.61K) | (55K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (19.95M) | (20.67M) | (111.21M) | (166.41M) |
| Sales of Investments | 13.5M | 0 | 36.18M | 0 | 118.48M |
| Other Investing Activities | (17.55K) | (372K) | 958K | 93.82M | 0 |
| Investing Cash Flow | 11.71M | (20.5M) | 16.43M | (17.55M) | (47.99M) |
| Debt Repayment | (284.77K) | 0 | (174K) | 0 | 0 |
| Common Stock Issued | 41.73M | 52.58M | 25.33M | 113.54M | 15K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.45M | 52.58M | 25.16M | 113.54M | 15K |
| Effect of Forex Changes | (141.71K) | (8.12M) | (3.02M) | 47.95K | 195K |
| Net Change in Cash | 62.2M | (33.08M) | (785K) | 41.98M | (110.05M) |
| Free Cash Flow | 7.39M | (57.59M) | (39.4M) | (54.22M) | (62.33M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$88.6M
+ D&A$555.0K
+ Stock-Based Comp$8.1M
+ Deferred Tax$11.0K
+ Working Capital$10.2M
+ Other Non-Cash$7.5M
= Operating Cash Flow-$62.3M
- Capex-$55.0K
= Free Cash Flow-$62.3M
Analysis
FY2025 free cash flow is -$62.3M. FCF conversion is 70.3% of net income. Operating cash flow was -$62.3M, with capex of -$55.0K. The largest bridge item is Working Capital at $10.2M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 13, 2026 | |
| DEFA14A | DEFA14A filing | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 5, 2026 |
Does SLN generate free cash flow?
Silence Therapeutics plc (SLN) generated -$62.33M of free cash flow in fiscal 2025.
How much operating cash flow does SLN produce?
Operating cash flow was -$62.27M, before capital expenditures of $55,000.00.
Continue the stock analysis
Jump to another research area for this company.